Findings

What do systematic reviews say?

31 questions · 32 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 9.4%GRADE not reported 3 · 9.4%Very low 19 · 59.4%Low 2 · 6.3%Moderate 5 · 15.6%High 0 · 0%

Selective serotonin reuptake inhibitors vs placebo

Leaving the study early · adults with panic disorder

Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.99 [0.9, 1.09]
23 studies · 4302 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Failure to remit at endpoint · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.81 [0.75, 0.88]
16 studies · 3339 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

panic symptoms · adults with panic disorder

2 findings from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1625 participants
Moderate
Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1255 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Withdrawals due to adverse events · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 1.45 [1.16, 1.81]
22 studies · 4131 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Subjective sleep quality or quantity · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 135 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Adverse events (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

PSG sleep outcomes (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a continuous outcome · patients with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 237 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low